With its ongoing and currently planned clinical programs and $270.3M in cash, cash equivalents and investments as of September 30 , the company anticipates sufficient resources to fund its planned operations into the second quarter of 2025.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on KRON:
